PriceTargets.com logo

Yarrow Bioscience - YARW Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $58.00
  • Forecasted Upside: 114.74%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$27.01 As of 09/11/2026 05:00 PM ET
▼ -1.43 (-5.03%)

This chart shows the closing price for YARW by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Yarrow Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for YARW and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for YARW

Analyst Price Target is $58.00
▲ +114.74% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Yarrow Bioscience in the last 3 months. The average price target is $58.00, with a high forecast of $58.00 and a low forecast of $58.00. The average price target represents a 114.74% upside from the last price of $27.01.

This chart shows the closing price for YARW for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Yarrow Bioscience. This rating has held steady since July 2026, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/19/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/17/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/16/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/16/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
6/14/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/13/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/12/2026

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/3/2026BTIG ResearchInitiated CoverageHold ➝ Buy$58.00
7/28/2026TD CowenInitiated CoverageBuy
5/4/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/21/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
7/31/2025BTIG ResearchDowngradeBuy ➝ Neutral
7/30/2025Lifesci CapitalDowngradeStrong-Buy ➝ Hold
7/30/2025HC WainwrightDowngradeBuy ➝ Neutral
4/25/2025HC WainwrightLower TargetBuy ➝ Buy$287.50 ➝ $225.00
3/6/2025HC WainwrightReiterated RatingBuy ➝ Buy$287.50 ➝ $287.50
2/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$287.50 ➝ $287.50
1/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$287.50 ➝ $287.50
1/6/2025HC WainwrightReiterated RatingBuy ➝ Buy$287.50 ➝ $287.50
12/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$287.50 ➝ $287.50
11/18/2024BTIG ResearchInitiated CoverageBuy$400.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$287.50 ➝ $287.50
9/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$287.50 ➝ $287.50
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$287.50 ➝ $287.50
6/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$287.50 ➝ $287.50
6/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$287.50 ➝ $287.50
5/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$287.50
2/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$287.50
10/30/2023HC WainwrightLower TargetBuy ➝ Buy$1,400.00 ➝ $287.50
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$1,400.00
5/12/2023Cantor FitzgeraldBoost Target$250.00 ➝ $450.00
4/19/2023HC WainwrightReiterated RatingBuy$1,400.00
3/30/2023HC WainwrightReiterated RatingBuy$1,400.00
3/14/2023HC WainwrightReiterated RatingBuy$1,400.00
8/12/2022Lifesci CapitalDowngradeOutperform ➝ Market Perform
8/10/2022HC WainwrightLower TargetBuy$6,300.00 ➝ $1,350.00
6/17/2022HC WainwrightReiterated RatingBuy$6,300.00
3/18/2022Cantor FitzgeraldReiterated RatingOverweight
12/6/2021HC WainwrightReiterated RatingBuy$6,300.00
(Data available from 9/13/2021 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/15/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/17/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/16/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/16/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/15/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/15/2026
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/14/2026
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/13/2026

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Yarrow Bioscience logo
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Read More

Today's Range

Now: $27.01
Low: $26.00
High: $27.49

50 Day Range

MA: N/A

52 Week Range

Now: $27.01
Low: $14.68
High: $46.95

Volume

1,364,922 shs

Average Volume

39,080 shs

Market Capitalization

$72.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Yarrow Bioscience?

The following sell-side analysts have issued reports on Yarrow Bioscience in the last year: BTIG Research, TD Cowen, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for YARW.

What is the current price target for Yarrow Bioscience?

0 Wall Street analysts have set twelve-month price targets for Yarrow Bioscience in the last year. Their average twelve-month price target is $58.00, suggesting a possible upside of 114.7%. BTIG Research has the highest price target set, predicting YARW will reach $58.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $58.00 for Yarrow Bioscience in the next year.
View the latest price targets for YARW.

What is the current consensus analyst rating for Yarrow Bioscience?

Yarrow Bioscience currently has 1 sell rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in YARW, but not buy more shares or sell existing shares.
View the latest ratings for YARW.

What other companies compete with Yarrow Bioscience?

Other companies that are similar to Yarrow Bioscience include Immuneering, Emergent Biosolutions, Myriad Genetics, Galectin Therapeutics and Bicycle Therapeutics. Learn More about companies similar to Yarrow Bioscience.

How do I contact Yarrow Bioscience's investor relations team?

Yarrow Bioscience's physical mailing address is 685 ROUTE 202/206, SUITE 301A, BRIDGEWATER, NJ, 08807. The company's listed phone number is (800) 775-7936 and its investor relations email address is [email protected]. The official website for Yarrow Bioscience is vynetherapeutics.com. Learn More about contacing Yarrow Bioscience investor relations.